



## GILUPI will attend at the ACTC congress in Rhodes

GILUPI GmbH is pleased to announce its participation at the 2017 ACTC (Advances in Circulating Tumor Cells) congress.

The 3rd ACTC meeting will take place from 4<sup>th</sup> to 7<sup>th</sup> October in Rhodes, Greece and is focused on "Liquid Biopsy in clinical practice". This congress brings together researchers, clinicians and companies, to discuss practical implementation of CTCs (circulating tumor cells) and ctDNA (circulating tumor DNA) and translate much of the excellent basic research in this field into clinical practice.

GILUPI will use this opportunity to present interim data from a clinical trial at the SRH Wald-Klinikum Gera - a certified lung cancer center in Germany. The clinical investors Dr. med. habil. Thomas Lesser and Dr. med. Julia Herrmann using the GILUPI CellCollector<sup>®</sup>, to monitor CTC counts before and after surgery in non-small cell lung cancer (NSCLC) patients. First results from 20 patients show that CTCs were isolated independent from cancer grade and could even be detected in quite early tumor stages. The difference between CTC occurrence before and after surgery suggested the possibility to identify patients responding to therapy or patients with stable disease. Moreover, a correlation between CTC numbers and clinical lack of recurrence was observed. In addition, patients were tested positive for PD-L1 (Programmed death-ligand 1 / CD274) expression in CTCs.

The poster presentation will take place on Thursday 5<sup>th</sup> of October at 3.30 pm - 4.30 pm. You are invited to meet Dr. Johanna Schiller from the GILUPI R&D department.

### About GILUPI GmbH

GILUPI GmbH is a medical device company founded in 2006 with focus on the development and production of innovative products for the *in vivo* isolation of rare cells from the blood circulation. Currently, the main focus of GILUPI is the diagnostics market for cancer.

Individual oncological targeted therapies become increasingly important in personalized medicine. The identification of the right drug for the individual patient is today's challenge in clinical practice. To address this medical need, the GILUPI CellCollector<sup>®</sup> is used to enrich rare cells by immuno-capture directly in the patient's bloodstream. This methodology has proven to yield highest cell numbers and patient positivity rates in various cancer types. Applying diagnostic analyses ranging from immunostaining, DNA- and RNA-based methods, isolated cells can be characterized and/or analyzed down to a molecular level.

The GILUPI CellCollector<sup>®</sup> is the first *in vivo* CTC isolation product worldwide that is CE approved.

For further information visit [www.gilupi.com](http://www.gilupi.com)